The UK Medicines and Healthcare products Regulatory Agency has released an updated public registry of authorised medicine brokers, reinforcing oversight mechanisms designed to safeguard the pharmaceutical supply chain. This transparency initiative requires all intermediaries involved in medicine transactions to maintain active MHRA registration and public listing, creating a verifiable network that healthcare providers can reference when sourcing medications.
The registry serves as a critical defense against counterfeit medicines, a global health threat identified by the World Health Organization as a serious risk to patient safety. By consolidating company names, registration details, and addresses in an accessible format, the MHRA enables supply chain partners to confirm broker legitimacy before engagement. This measure complements existing protections including serialization requirements and good distribution practices, creating layered safeguards throughout the medicine distribution pathway.
Read the full article on GMJ Newsroom.
Was this article helpful?
